

October 14, 2022

Dear Colleague,

The Centers for Disease Control and Prevention (CDC) has expanded the recommendation for bivalent COVID-19 booster doses to include children ages 5 to 11 years. According to the new recommendations, everyone 5 years of age and older should receive one age-appropriate bivalent mRNA COVID-19 booster dose at least 2 months after completion of a monovalent COVID-19 primary series or previously received monovalent booster dose. Age-appropriate homologous and heterologous boosters are allowed; there is no preference for homologous or heterologous boosters. Monovalent booster doses are no longer authorized for any ages.

The CDC's <u>Clinical Considerations</u> have also been updated, including revised COVID-19 vaccination schedules for <u>people who are not immunocompromised</u> and <u>people who are immunocompromised</u>. The recommendations for children under 5 years of age are unchanged; children under 5 years of age are not recommended to receive any type of booster at this time.

The bivalent boosters contain two mRNA components of SARS-CoV-2 virus: one of the ancestral strain of SARS-CoV-2 and one of common portions of the BA.4 and BA.5 lineages of the Omicron variant. Three bivalent booster formulations have received <a href="Emergency Use Authorization">Emergency Use Authorization</a> (EUA) from the U.S. Food and Drug Administration to date:

- Moderna bivalent booster (dark blue cap, gray label border): no dilution, storage in a freezer (-15°C to -50°C) until expiration or refrigerator (2°C to 8°C) up to 30 days
  - o Ages 6 to 11 years: 25 mcg / 0.25 mL dose
  - Ages 12 years and older: 50 mcg / 0.5 mL dose
- **Pfizer bivalent booster (orange cap):** dilution required, storage in an ultra-cold freezer until expiration or refrigerator (2°C to 8°C) up to 10 weeks
  - Ages 5 to 11 years: 10 mcg / 0.2 mL dose
- **Pfizer bivalent booster (gray cap):** no dilution, storage in an ultra-cold freezer until expiration or refrigerator (2°C to 8°C) up to 10 weeks
  - Ages 12 years and older: 30 mcg / 0.3 mL dose

Given that the bivalent formulations have the same or similar cap colors as the monovalent formulations for each manufacturer and dosing varies by product and age group, **providers** must pay careful attention to the vial labels to prevent vaccine administration errors.

Giving multiple vaccines at the same visit increases the chance that a person will be up to date with their vaccinations. Coadministration of the flu and COVID-19 vaccines will help ensure that people, especially older adults and others at increased risk of complications from both viruses, are protected. COVID-19 vaccines administered with seasonal flu vaccine showed similar immunogenicity and similar or slightly higher reactogenicity; no safety concerns were identified.

We will hold office hours on Tuesday, October 18 from 8:30-9:30 a.m. to answer providers' questions about bivalent booster recommendations.

- You can join the office hours at this meeting <u>link</u> or by calling 646-992-2010.
- The meeting number is 2346 541 8871 and the password is "Dohmh123."

If you are enrolled in the COVID-19 vaccination program, please order bivalent booster vaccine for your patient population in the <u>Citywide Immunization Registry</u>. If you do not have vaccine at your facility, make sure to refer patients to a vaccination site. To find a vaccination site, visit <u>vaccinefinder.nyc.gov</u> or call 877-VAX-4NYC (877-829-4692).

Thank you for continuing to promote and protect the health of New Yorkers.

Sincerely,

Jane R. Zucker, MD, MSc

Jane R. Ziden

**Assistant Commissioner** 

Bureau of Immunization

New York City Department of Health and Mental Hygiene